Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms
Executive Summary
Merck is edging away from its strict go-it-alone policy and sidling up a little closer to Schering-Plough in a series of deals - the most recent of which is a co-promotion agreement with Schering-Plough for the Phase III cholesterol absorption inhibitor ezetimibe.
You may also be interested in...
Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck
Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category
Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck
Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category
Merck Adds To Phase III Pipeline With Lundbeck Sleep-Aid Gaboxadol
Merck's $270 mil. licensing deal for Lundbeck's Phase III sleep disorder agent gaboxadol could give Merck a fifth new product approval around the time that Zocor comes off patent